BR112017000667A2 - method for modulating, promoting or ameliorating or suppressing or preventing immunity, for treating or preventing a disease, dysfunction or condition in a mammal, a method for designing, screening, genetically engineering or otherwise producing an agonist, inhibitor or antagonist of galectin-9, galectin-9 agonist, antagonist or inhibitor and composition - Google Patents
method for modulating, promoting or ameliorating or suppressing or preventing immunity, for treating or preventing a disease, dysfunction or condition in a mammal, a method for designing, screening, genetically engineering or otherwise producing an agonist, inhibitor or antagonist of galectin-9, galectin-9 agonist, antagonist or inhibitor and compositionInfo
- Publication number
- BR112017000667A2 BR112017000667A2 BR112017000667-7A BR112017000667A BR112017000667A2 BR 112017000667 A2 BR112017000667 A2 BR 112017000667A2 BR 112017000667 A BR112017000667 A BR 112017000667A BR 112017000667 A2 BR112017000667 A2 BR 112017000667A2
- Authority
- BR
- Brazil
- Prior art keywords
- galectin
- mammal
- cells
- antagonist
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1732—Lectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014902709A AU2014902709A0 (en) | 2014-07-14 | Galectin immunotherapy | |
| AU2014902709 | 2014-07-14 | ||
| AU2014904466A AU2014904466A0 (en) | 2014-11-06 | Galectin immunotherapy | |
| AU2014904466 | 2014-11-06 | ||
| PCT/AU2015/050393 WO2016008005A1 (en) | 2014-07-14 | 2015-07-14 | Galectin immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017000667A2 true BR112017000667A2 (en) | 2018-01-09 |
Family
ID=55077738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017000667-7A BR112017000667A2 (en) | 2014-07-14 | 2015-07-14 | method for modulating, promoting or ameliorating or suppressing or preventing immunity, for treating or preventing a disease, dysfunction or condition in a mammal, a method for designing, screening, genetically engineering or otherwise producing an agonist, inhibitor or antagonist of galectin-9, galectin-9 agonist, antagonist or inhibitor and composition |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170152317A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3169349A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2017521445A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170040796A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106999548A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015291783B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017000667A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2954678A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201700281SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016008005A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180044422A1 (en) * | 2016-07-29 | 2018-02-15 | New York University | Treating solid tumor by targeting dectin-1 signaling |
| CN118085109A (zh) * | 2016-08-11 | 2024-05-28 | 昆士兰医学研究所理事会 | 免疫调节化合物 |
| WO2018027281A1 (en) * | 2016-08-11 | 2018-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune status biomarkers and uses therefor |
| WO2019084553A1 (en) | 2017-10-27 | 2019-05-02 | New York University | ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF |
| KR20220030934A (ko) * | 2019-05-31 | 2022-03-11 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 항-gal9 면역-억제 결합 분자 |
| SG11202113222PA (en) * | 2019-05-31 | 2021-12-30 | Council Queensland Inst Medical Res | Activating anti-gal9 binding molecules |
| WO2021022256A1 (en) * | 2019-08-01 | 2021-02-04 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101070540B (zh) * | 2000-04-28 | 2015-04-01 | 约翰霍普金斯大学 | 新的树突状细胞共刺激分子 |
| US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| WO2002000692A2 (en) * | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: pd-1 ligands and uses therefor |
| JP2003189874A (ja) * | 2001-12-28 | 2003-07-08 | Galpharma Co Ltd | ガレクチン−9活性制御剤 |
| CA2514108A1 (en) * | 2003-01-24 | 2004-08-05 | Galpharma Co., Ltd. | Drugs containing galectin 9 |
| KR20060011977A (ko) * | 2003-04-28 | 2006-02-06 | 가르파마 컴퍼니 리미티드 | 갈렉틴 9 유도 인자 |
| EP2889309B1 (en) * | 2006-03-03 | 2017-12-27 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of pd-1 or pd-l1 |
| JP2011514895A (ja) * | 2008-02-29 | 2011-05-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 精製免疫グロブリン融合タンパク質およびその精製方法 |
| WO2010098788A2 (en) * | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2010084999A1 (en) * | 2009-01-26 | 2010-07-29 | Protegene, Inc. | Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases |
| EP2504028A4 (en) * | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| KR20130103587A (ko) * | 2010-12-09 | 2013-09-23 | 가르파마 컴퍼니 리미티드 | 갈렉틴 9를 분비하는 세포, 그 제조 방법 및 그 용도 |
| WO2012177788A1 (en) * | 2011-06-20 | 2012-12-27 | La Jolla Institute For Allergy And Immunology | Modulators of 4-1bb and immune responses |
-
2015
- 2015-07-14 CA CA2954678A patent/CA2954678A1/en not_active Abandoned
- 2015-07-14 WO PCT/AU2015/050393 patent/WO2016008005A1/en not_active Ceased
- 2015-07-14 US US15/325,789 patent/US20170152317A1/en not_active Abandoned
- 2015-07-14 BR BR112017000667-7A patent/BR112017000667A2/en not_active IP Right Cessation
- 2015-07-14 KR KR1020177003994A patent/KR20170040796A/ko not_active Withdrawn
- 2015-07-14 JP JP2017502240A patent/JP2017521445A/ja active Pending
- 2015-07-14 CN CN201580048553.7A patent/CN106999548A/zh active Pending
- 2015-07-14 EP EP15822359.4A patent/EP3169349A4/en not_active Withdrawn
- 2015-07-14 AU AU2015291783A patent/AU2015291783B2/en not_active Ceased
- 2015-07-14 SG SG11201700281SA patent/SG11201700281SA/en unknown
-
2018
- 2018-12-19 US US16/226,302 patent/US20190127474A1/en not_active Abandoned
-
2021
- 2021-04-14 JP JP2021068435A patent/JP2021105055A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017521445A (ja) | 2017-08-03 |
| AU2015291783B2 (en) | 2018-07-26 |
| EP3169349A4 (en) | 2018-02-14 |
| US20190127474A1 (en) | 2019-05-02 |
| AU2015291783A1 (en) | 2017-03-02 |
| EP3169349A1 (en) | 2017-05-24 |
| SG11201700281SA (en) | 2017-02-27 |
| CA2954678A1 (en) | 2016-01-21 |
| KR20170040796A (ko) | 2017-04-13 |
| JP2021105055A (ja) | 2021-07-26 |
| WO2016008005A1 (en) | 2016-01-21 |
| US20170152317A1 (en) | 2017-06-01 |
| CN106999548A (zh) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190127474A1 (en) | Galectin immunotherapy | |
| Ko et al. | Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells | |
| WO2020072700A1 (en) | Hla single allele lines | |
| Wang et al. | Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway | |
| Green et al. | Neonatal tumor necrosis factor α promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8+ T cells | |
| WO2003006632A2 (en) | Methods and compisitions for activation human t cells in vitro | |
| Zhang et al. | Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent | |
| WO2014052545A2 (en) | Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis | |
| JP2015516376A (ja) | T細胞エピトープを含む、b細胞受容体複合体結合タンパク質 | |
| Gbedande et al. | Using two phases of the CD 4 T cell response to blood‐stage murine malaria to understand regulation of systemic immunity and placental pathology in Plasmodium falciparum infection | |
| Zhang et al. | Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB/c mice against acute toxoplasmosis | |
| Hwang et al. | CD8+ T cell immunity in an encephalitis model of Toxoplasma gondii infection | |
| Saha et al. | Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen | |
| WO2017136686A1 (en) | Cross-regulation of type i interferon signaling pathways | |
| AU2021281062B2 (en) | Immunomodulatory complex and uses thereof for therapy | |
| EP2537932B1 (en) | Compositions for and methods of identifying antigens | |
| Wykes et al. | Adaptive immunity to Plasmodium blood stages | |
| CA2798932A1 (en) | The n-domain of carcinoembryonic antigen and compositions, methods and uses thereof | |
| Lapke et al. | The application of anti-Toso antibody enhances CD8+ T cell responses in experimental malaria vaccination and disease | |
| Gbedande et al. | Boosting Live Malaria Vaccine with Cytomegalovirus Vector Can Prolong Immunity through Innate and Adaptive Mechanisms | |
| Tuma et al. | Rescue of CD8 T cell–mediated antimicrobial immunity with a nonspecific inflammatory stimulus | |
| Jo | EXPLORING NOVEL CELLULAR THERPEUTICS FOR IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MYOCARDITIS: INVESTIGATING TIGIT OVEREXPRESSION IN T CELLS | |
| Poston | T-cell Dependent and independent mechanisms of chlamydial eradication and control | |
| Gajdasik | Investigating costimulatory molecule provision and regulation for CD4 T cell responses in vivo | |
| Wang | Blockade of CD200-CD200R1 signaling axis can upregulate phagocytosis of cancer cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2679 DE 10-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |